Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 21
Filtrar
1.
Dermatol Online J ; 27(4)2021 Apr 15.
Artigo em Inglês | MEDLINE | ID: mdl-33999584

RESUMO

Sporothrix spp. cause the most common deep fungal skin infections in Brazil and this is related to infected cats. Transmission is traditionally from organic material/plants but can also be zoonotic. Culture of a skin biopsy is the golden standard for determination. Treatment with oral itraconazole approaches up to 95% efficacy in patients with cutaneous sporotrichosis.


Assuntos
Carbúnculo/microbiologia , Doenças do Gato/transmissão , Gatos/microbiologia , Sporothrix/isolamento & purificação , Esporotricose/transmissão , Zoonoses/transmissão , Animais , Antifúngicos/uso terapêutico , Brasil , Carbúnculo/patologia , Diagnóstico Diferencial , Doenças Endêmicas , Feminino , Humanos , Itraconazol/uso terapêutico , Pessoa de Meia-Idade , Pele/microbiologia , Pele/patologia , Esporotricose/diagnóstico , Esporotricose/tratamento farmacológico , Esporotricose/patologia
3.
Dermatol Online J ; 17(12): 5, 2011 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-22233741

RESUMO

Tacrolimus ointment 0.1 percent is a well-established topical therapy for treating atopic dermatitis. Efficacy and safety have been described in several trials. Here, we present a patient with rapid onset of extensive varicella zoster infection in tacrolimus-treated skin: a side effect that has only occasionally been reported. Early recognition is important because rapid treatment for herpes zoster may lead to less frequent post-herpetic neuralgia and serious complications.


Assuntos
Fármacos Dermatológicos/efeitos adversos , Herpes Zoster/induzido quimicamente , Herpesvirus Humano 3/isolamento & purificação , Tacrolimo/efeitos adversos , Aciclovir/análogos & derivados , Aciclovir/uso terapêutico , Antivirais/uso terapêutico , Dermatite Atópica/tratamento farmacológico , Fármacos Dermatológicos/uso terapêutico , Quimioterapia Combinada , Feminino , Ácido Fusídico/uso terapêutico , Herpes Zoster/diagnóstico , Herpes Zoster/tratamento farmacológico , Herpesvirus Humano 3/efeitos dos fármacos , Humanos , Pessoa de Meia-Idade , Pomadas , Tacrolimo/uso terapêutico , Resultado do Tratamento , Valaciclovir , Valina/análogos & derivados , Valina/uso terapêutico
4.
J Eur Acad Dermatol Venereol ; 24(4): 439-44, 2010 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-19845822

RESUMO

BACKGROUND: Safety and clinical effectiveness of clobetasol-17 propionate 0.05% shampoo have been shown in patients with scalp psoriasis. AIM: First, to evaluate treatment satisfaction, user convenience safety and effectiveness of clobetasol-17 propionate 0.05% shampoo treatment in daily clinical practice. Second, to identify subgroup variables that may predict treatment success or failure. METHODS: A total of 56 patients with scalp psoriasis were treated with short-contact clobetasol-17 propionate 0.05% shampoo once daily for 4 weeks. Data on treatment satisfaction, user convenience, safety and effectiveness were assessed on a 7-point Likert scale using postal questionnaires. Subgroup analyses were performed to identify variables that may predict treatment outcome. RESULTS: A total of 41 patients returned both questionnaires (73%). Positive treatment satisfaction and user convenience were reported by 66% and 79% of patients respectively. Patient-rated indicators for disease severity improved by 39-46% (P < 0.05%). No major side-effects were reported. Subgroup analyses did not reveal any statistically significant patient variable that may predict treatment outcome. However, a tendency towards improved treatment satisfaction was observed in patients who had received fewer topical antipsoriatic treatments previously (P > 0.05). CONCLUSIONS: Short-contact treatment with clobetasol-17 propionate 0.05% shampoo has high user convenience and patient satisfaction rates. Moreover, the treatment is well-tolerated and efficacious from patients' perspective. Subgroup analyses did not reveal factors predicting treatment outcome, although treatment success tended to be more evident in patients who had received fewer treatments previously.


Assuntos
Anti-Inflamatórios/administração & dosagem , Clobetasol/administração & dosagem , Satisfação do Paciente , Psoríase/tratamento farmacológico , Dermatoses do Couro Cabeludo/tratamento farmacológico , Administração Tópica , Adulto , Anti-Inflamatórios/efeitos adversos , Clobetasol/efeitos adversos , Estudos Transversais , Esquema de Medicação , Feminino , Preparações para Cabelo , Humanos , Masculino , Índice de Gravidade de Doença , Inquéritos e Questionários
5.
Dermatol Online J ; 16(10): 2, 2010 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-21062596

RESUMO

In rare cases, cutaneous larva migrans may be complicated by Löffler syndrome. This syndrome is thought to result from a type I hypersensitivity reaction related to the pulmonary larval migration phase of various parasites. It is characterized by migratory pulmonary eosinophilic infiltrates and peripheral eosinophilia, with malaise, fever, and cough. Our patient was successfully treated with ivermectin, a corticosteroid cream, and inhalation medication in an early phase, which prevented complications. We present the details of this case and review the literature.


Assuntos
Larva Migrans/complicações , Eosinofilia Pulmonar/diagnóstico , Eosinofilia Pulmonar/etiologia , Corticosteroides/uso terapêutico , Adulto , Antiasmáticos/uso terapêutico , Anti-Inflamatórios/uso terapêutico , Antiparasitários/uso terapêutico , Budesonida/uso terapêutico , Combinação Budesonida e Fumarato de Formoterol , Clobetasol/uso terapêutico , Combinação de Medicamentos , Etanolaminas/uso terapêutico , Humanos , Ivermectina/uso terapêutico , Larva Migrans/tratamento farmacológico , Masculino , Eosinofilia Pulmonar/tratamento farmacológico
6.
J Dermatolog Treat ; 31(4): 378-381, 2020 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-30957595

RESUMO

Background: Dimethylfumarate (DMF) is an effective treatment for psoriasis, which may cause side effects in a considerable group of patients. Alterations in white blood cell (WBC) counts may predict treatment success and the occurrence of side effects.Objectives: To analyze WBC counts with respect to efficacy and the prevalence of side effects during DMF therapy for psoriasis.Methods and materials: Psoriasis patients were treated with DMF. Retrospective data (WBC counts, treatment results, and side effects) were analyzed to assess correlations with respect to efficacy, tolerability, and leukocyte subsets.Results: Of 95 patients treated with DMF, 60 patients (63.2%) had treatment success at week 16 and 77 patients (81.1%) experienced side effects. Absolute lymphocyte counts were more decreased in the treatment success group versus the treatment failure group: 1.1 (±0.7 SD) versus 0.6 (±0.6 SD); p<.05. Eosinophil counts were more increased in the group with side effects versus the group without side effects: 3.8 (±5.5 SD) versus 1.2 (±2.5 SD); p<.05. However, direct correlation studies showed no statistically significant correlations.Conclusions: Lymphopenia is associated with better clinical results of DMF treatment for psoriasis, whereas eosinophilia is associated with the occurrence of side effects.


Assuntos
Fármacos Dermatológicos/uso terapêutico , Fumarato de Dimetilo/uso terapêutico , Eosinofilia , Linfopenia , Psoríase/tratamento farmacológico , Adulto , Biomarcadores , Feminino , Humanos , Contagem de Leucócitos , Masculino , Pessoa de Meia-Idade , Psoríase/imunologia , Estudos Retrospectivos , Resultado do Tratamento
8.
Arch Dermatol Res ; 298(9): 457-63, 2007 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-17136563

RESUMO

The aim of this study was to explore the additional effect of betamethasone dipropionate cream in the early phase of an intramuscular (IM) alefacept course, on plaque severity and on modulating T-cell subsets, cells expressing NK-receptors, epidermal proliferation and keratinocyte differentiation in lesional psoriatic skin. Therefore, sixteen patients with moderate-to-severe chronic plaque psoriasis received 15 mg alefacept IM for 12 weeks, followed by a 12-week follow-up period. The first 4 weeks, patients were randomized 1:1 to either betamethasone dipropionate, or the vehicle cream, once daily. Plaque severity (SUM) was assessed and serial biopsies were immunohistochemically stained for T-cell subsets (CD3, CD4, CD8, CD45RO, CD45RA, CD2, CD25, GITR), cells expressing NK-receptors (CD94 and CD161), epidermal proliferation (Ki67) and differentiation (K10), which were quantified using manual and digital image analysis. Alefacept monotherapy resulted in statistically significant improvement in plaque severity. Subsequently, immunohistochemical assessments on T-cell subsets, epidermal proliferation (Ki67) and keratinization (K10) revealed marked time-related improvements with respect to the mentioned parameters, without significant differences between both treatment regimens. Alefacept monotherapy induces improvement of plaque severity, which is accompanied by a reduction in activated (CD2+, CD25+, CD45RO+) dermal CD4+ and activated epidermal CD8+ T cells, epidermal proliferation and differentiation. Once daily treatment with betamethasone dipropionate cream during the first 4 weeks of an intramuscular alefacept course did not provide substantial additional clinical and immunohistochemical improvement.


Assuntos
Anti-Inflamatórios/farmacologia , Betametasona/análogos & derivados , Fármacos Dermatológicos/uso terapêutico , Psoríase/tratamento farmacológico , Proteínas Recombinantes de Fusão/uso terapêutico , Administração Tópica , Adulto , Alefacept , Anti-Inflamatórios/administração & dosagem , Antígenos CD/efeitos dos fármacos , Antígenos CD/metabolismo , Betametasona/administração & dosagem , Betametasona/farmacologia , Diferenciação Celular/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Fármacos Dermatológicos/administração & dosagem , Método Duplo-Cego , Quimioterapia Combinada , Epiderme/efeitos dos fármacos , Epiderme/crescimento & desenvolvimento , Humanos , Imuno-Histoquímica , Injeções Intramusculares , Queratinócitos/efeitos dos fármacos , Psoríase/patologia , Índice de Gravidade de Doença , Subpopulações de Linfócitos T/efeitos dos fármacos , Subpopulações de Linfócitos T/patologia , Resultado do Tratamento
10.
Eur J Dermatol ; 15(6): 454-8, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-16280298

RESUMO

With infliximab therapy (anti-TNF-alpha) for plaque psoriasis, over 80% of patients reach > or = 75% PASI improvement in 10 weeks of treatment. We describe a patient with severe recalcitrant psoriasis who was treated with infliximab 5 mg/kg for 22 weeks. Rather than the expected improvement, this patient experienced an initial exacerbation, followed by the lack of efficacy over the entire 22-week period of treatment. Before, during and after treatment we performed immunohistochemical analyses on lesional biopsies, with respect to T cells, NK-T cells, epidermal growth and differentiation. We found a discrepancy between the clinical aggravation and marked reductions of lesional T cell subsets. The most prominent decrease was for CD4+ T cells (72-74%), which suggests that a reduction of T cells in the psoriatic plaque might not be a guarantee for positive clinical outcomes. Remarkably, the number of epidermal CD94+ NK-T cells correlated fairly well with the lack of clinical efficacy, supposing a pathogenic role for these cells in psoriasis. Further studies are needed to clarify the ambiguous role of conventional pathogenic T cells in plaque psoriasis.


Assuntos
Anticorpos Monoclonais/uso terapêutico , Psoríase/tratamento farmacológico , Psoríase/imunologia , Linfócitos T/fisiologia , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Feminino , Humanos , Infliximab , Pessoa de Meia-Idade , Psoríase/patologia
11.
Aliment Pharmacol Ther ; 20(3): 311-9, 2004 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-15274668

RESUMO

BACKGROUND: Little is known about the variation in health-related quality of life among patients with different presentations of gastrointestinal symptoms. AIM: To study the association between health-related quality of life and presentations of gastrointestinal symptoms. METHODS: Health-related quality of life and demographic information was obtained from 873 patients referred to the hospital for endoscopy, using a questionnaire. RESULTS: A total of 436 patients (50%) reported predominantly upper gastrointestinal symptoms, 344 (39%) predominantly lower symptoms, and 93 (11%) patients reported both upper and lower symptoms. Patients with mild, moderate and severe symptoms, reported mean scores on a 100-point visual analogue scale (95% CI) of 90 (79-100), 75 (64-86) and 64 (53-76), respectively (P < 0.001). Mean visual analogue scale scores (95% CI) almost linearly declined from 81 (77-85) to 49 (46-52) for those with one to those with more than eight symptoms. Patients who reported upper gastrointestinal symptoms and in particular epigastric pain, bloating and vomiting had significantly impaired health status in comparison to patients without these symptoms (P < 0.05). CONCLUSIONS: Severity of gastrointestinal symptoms is the most important factor in affecting health status, followed by the numbers and type of gastrointestinal symptoms.


Assuntos
Gastroenteropatias/psicologia , Qualidade de Vida , Atividades Cotidianas , Feminino , Gastroenteropatias/complicações , Gastroenteropatias/terapia , Nível de Saúde , Humanos , Masculino , Pessoa de Meia-Idade , Países Baixos , Inquéritos e Questionários
14.
Ned Tijdschr Geneeskd ; 156(46): A4613, 2012.
Artigo em Holandês | MEDLINE | ID: mdl-23151326

RESUMO

A 33-year-old healthy woman consulted her dermatologist when an acute and painful perioral pustular dermatosis erupted one day after she had taken azitromycin for a throat infection. A preliminary diagnosis of acute localized exanthematous pustulosis (ALEP) was made, which was later confirmed by cultures and histopathological examination. Medication was cessated immediately and the dermatosis disappeared completely afterwards.


Assuntos
Antibacterianos/efeitos adversos , Azitromicina/efeitos adversos , Exantema/induzido quimicamente , Dermatopatias Vesiculobolhosas/induzido quimicamente , Adulto , Antibacterianos/uso terapêutico , Azitromicina/uso terapêutico , Exantema/diagnóstico , Feminino , Humanos , Dermatopatias Vesiculobolhosas/diagnóstico
15.
J Eur Acad Dermatol Venereol ; 21(8): 1038-46, 2007 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-17714122

RESUMO

BACKGROUND: R115866 (Rambazole) is a new generation all-trans retinoic acid metabolism blocking agent, highly specific against the retinoic acid 4-hydroxylase. The drug alleviates hyperproliferation and normalizes differentiation of the epidermis in animal models of psoriasis. OBJECTIVE: To explore the efficacy, safety and tolerability of systemic R115866 in patients with moderate to severe plaque-type psoriasis. PATIENTS AND METHODS: In this open label, single-arm trial, patients were treated with R115866, 1 mg/day for 8 weeks, followed by a 2-week treatment-free follow-up period. Patients were monitored for efficacy and safety. RESULTS: Nineteen patients (intent-to-treat population) were treated and 14 completed the entire study. Two patients discontinued due to lack of efficacy and three due to adverse events. At the end of the treatment, 26% of the patients showed at least 50% reduction in Psoriasis Area Severity Index (PASI) compared to baseline. Further improvement was observed at the end of the 2-week follow-up period where 47% of the patients showed a 50% or greater reduction in PASI. Kinetic data showed no evidence of accumulation of either R115866 or retinoic acid in plasma. The most common adverse events were pruritus, xerosis, cheilitis and an increase in blood triglycerides. The majority of adverse events were mild to moderate. No deaths or serious adverse events were reported. CONCLUSION: Eight-week daily treatment with 1 mg R115866 resulted in a significant reduction in PASI from baseline to end of therapy. Additional improvement was seen after the 2-week follow-up period. The drug was well tolerated. R115866 merits further evaluation to optimize its clinical efficacy and safety profile in moderate to severe plaque-type psoriasis.


Assuntos
Benzotiazóis/uso terapêutico , Fármacos Dermatológicos/uso terapêutico , Psoríase/tratamento farmacológico , Triazóis/uso terapêutico , Administração Oral , Adulto , Idoso , Benzotiazóis/administração & dosagem , Fármacos Dermatológicos/administração & dosagem , Relação Dose-Resposta a Droga , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Índice de Gravidade de Doença , Estatísticas não Paramétricas , Resultado do Tratamento , Triazóis/administração & dosagem
16.
Br J Dermatol ; 156(2): 263-70, 2007 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-17223865

RESUMO

BACKGROUND: The novel systemic all-trans retinoic acid metabolism blocking agent (RAMBA) R115866 (Rambazole(TM); Barrier Therapeutics, Geel, Belgium; further referred to as rambazole) increases intracellular levels of endogenous all-trans retinoic acid (RA). Well-known effects of RA are normalization of aberrant epithelial growth and differentiation. Hence, rambazole might be beneficial in the treatment of plaque psoriasis. OBJECTIVES: The dynamics of epidermal proliferation, keratinization, lesional T-cell subsets and cells expressing natural killer (NK)-receptors in plaque psoriasis were assessed during treatment with rambazole, as part of a phase IIa open-label clinical trial. METHODS: Six patients were treated with rambazole, 1 mg, once daily, for 8 weeks. At weeks 0, 2 and 8, psoriatic plaque severity scores (SUM) and biopsies from a target lesion were assessed. Epidermal proliferation (Ki67), keratinization markers (K10, K13, K19), T-cell subsets (CD3, CD4+, CD8+, CD45RO+, CD45RA+, CD2+, CD25+, GITR+) and cells expressing NK-receptors (CD94, CD161) were immunohistochemically stained and quantified with image analysis. RESULTS: At week 2 the mean SUM-score was virtually equal to baseline, which was accompanied immunohistochemically by equal epidermal hyperproliferation, a nonsignificant decrease in K10 positive epidermis and, overall, a nonsignificant increase in immunocyte subsets. At week 8, in contrast, plaque severity was reduced by 34% from baseline (P < 0.05). Improvements were also detected for epidermal proliferation (-63%; P < 0.01) and K10 expression (+29%; P < 0.01), compared with baseline. No induction of retinoid-specific keratinization (K13, K19) was observed. A nonsignificant reduction of all pathogenic T-cell subsets and cells expressing NK-receptors was observed at week 8 of treatment (P > 0.05). CONCLUSIONS: Clinical efficacy of rambazole is primarily the result of restoring proliferation (Ki67) and differentiation (K10) of epidermal keratinocytes. Secondly, relevant T-cell subsets and cells expressing NK-receptors showed nonsignificant reductions after 8 weeks of treatment with rambazole.


Assuntos
Benzotiazóis/administração & dosagem , Fármacos Dermatológicos/administração & dosagem , Ceratolíticos/antagonistas & inibidores , Psoríase/tratamento farmacológico , Tretinoína/antagonistas & inibidores , Triazóis/administração & dosagem , Administração Oral , Adulto , Proliferação de Células/efeitos dos fármacos , Feminino , Humanos , Imuno-Histoquímica/métodos , Masculino , Pessoa de Meia-Idade
17.
Br J Dermatol ; 155(1): 110-4, 2006 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-16792761

RESUMO

BACKGROUND: Localized chronic plaque psoriasis, resistant to local therapy, may be very hard to treat. The treatment of these lesions with a pulsed dye laser (PDL) has been described before, but a comparative study between the PDL and a potent topical treatment has never been performed. OBJECTIVES: To compare the efficacy of the PDL in the treatment of localized, recalcitrant plaque psoriasis with a potent topical therapy, using calcipotriol/betamethasone dipropionate (Dovobet) as an active comparator. METHODS: Eight patients with psoriasis were treated with both PDL (585 nm) and calcipotriol/betamethasone dipropionate in an open, intrapatient, left-right comparison. A plaque severity score (sum score) and photographs were used to document the course of therapy. Patients reported pain on a visual analogue scale. RESULTS: Both treatments were well tolerated, although one patient left the study due to post-PDL treatment pain. A significant difference in the sum score 12 weeks after treatment was seen in favour of the PDL (62% vs. 19% reduction; P<0.05). Scores for erythema declined significantly at week 12 in both the PDL and the calcipotriol/betamethasone dipropionate group (P<0.001). Induration and desquamation scores were significantly reduced at week 12 in the PDL group, without a statistically significant reduction in calcipotriol/betamethasone-treated lesions. The pain scores declined with progressive PDL treatments, although not statistically significantly. CONCLUSIONS: PDL treatment might be considered for the treatment of localized, recalcitrant plaque psoriasis, when other topical therapies have failed.


Assuntos
Terapia a Laser , Psoríase/terapia , Adulto , Análise de Variância , Anti-Inflamatórios/uso terapêutico , Betametasona/uso terapêutico , Calcitriol/análogos & derivados , Calcitriol/uso terapêutico , Fármacos Dermatológicos/uso terapêutico , Combinação de Medicamentos , Feminino , Seguimentos , Humanos , Masculino , Pessoa de Meia-Idade , Psoríase/tratamento farmacológico , Resultado do Tratamento
18.
Dermatology ; 213(2): 111-7, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-16902287

RESUMO

BACKGROUND: Depletion of CD4+ CD25+ Foxp3+ naturally occurring regulatory T cells (T(reg)) induces autoimmune phenomena. These cells have not yet been fully characterized in the skin of psoriatic patients. OBJECTIVES: To prove that the Zenon immunofluorescent labeling technique is suitable for the demonstration of co-localization of T-cell markers and in particular to show the distribution of T(reg) in psoriatic skin. METHODS: In biopsies derived from normal and psoriatic skin, CD4+ CD25+, CD4+ CD45RO+, CD8+ CD25+, CD8+ CD45RO+ and CD4+ CD25+ Foxp3+ cells in the dermis and in the epidermis were immunophenotyped, using a quantitative immunofluorescent labeling technique (Zenon), analyzed and compared using image analysis. RESULTS: The immunofluorescent labeling technique was shown to be an easy and reliable tool to demonstrate co-localization of T-cell markers. In psoriasis, all pathogenic T-cell subsets (CD4+ CD25+, CD4+ CD45RO+, CD8+ CD25+ and CD8+ CD45RO+ cells) were significantly increased in the dermis and in the epidermis, as compared to normal skin (all p < 0.05). Using this labeling technique we were able to reveal CD4+ CD25+ Foxp3+ T(reg) in psoriatic dermis, but not in the dermis of normal skin (p < 0.0001). CONCLUSIONS: The Zenon immunofluorescence technique in combination with image analysis is suitable for the demonstration of co-localization of T-cell markers in tissue. Increased numbers of pathogenic T cells (CD4+ CD25+, CD4+ CD45RO+, CD8+ CD25+ and CD8+ CD45RO+) were shown in the dermis and epidermis, whereas CD4+ CD25+ Foxp3+ T(reg) were identified in psoriatic skin with a predilection for the upper dermis.


Assuntos
Antígenos CD4/metabolismo , Fatores de Transcrição Forkhead/metabolismo , Subunidade alfa de Receptor de Interleucina-2/metabolismo , Psoríase/imunologia , Linfócitos T Reguladores/imunologia , Adulto , Biomarcadores/metabolismo , Biópsia , Epiderme/metabolismo , Epiderme/patologia , Feminino , Humanos , Masculino , Microscopia de Fluorescência , Psoríase/metabolismo , Psoríase/patologia , Linfócitos T Reguladores/metabolismo
19.
Dig Dis Sci ; 51(9): 1509-15, 2006 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16927133

RESUMO

Questionnaires are widely used instruments to monitor gastrointestinal (GI) symptoms. However, few of these questionnaires have been formally evaluated. We sought to evaluate our GI symptoms questionnaire in terms of clarity and reproducibility. Primary care patients referred for open access Helicobacter pylori urea breath testing reported GI symptoms (type+severity) and demographic information by written questionnaire. In an interview, patients gave a personal description of the meaning of the GI symptoms on the questionnaire. Patients' descriptions of GI symptoms were compared with current definitions. Symptom severity scores were compared before and after, interview versus questionnaire. Of the 45 patients included, 19 (42%) described all symptoms correctly, whereas 17 (38%) described one symptom incorrectly. None of the patients made more than three mistakes. Regurgitation was the most common incorrectly described symptom (16 patients [36%]), whereas the other individual symptoms were well explained. Symptom severities before the interview, after the interview and reported by questionnaire (mean value+/-SEM) were 2.1 +/- 0.2, 2.1 +/- 0.2, and 1.5 +/- 0.2 points on a 7-point Likert scale (0-6), respectively. Mean severity reported by interview (95% CI) was 1.4 (1.3-1.5) times higher than reported by questionnaire (P < .05). In conclusion, the GI symptom questionnaire is understandable and has good reproducibility for measuring the presence of GI symptoms, although symptom severity is consistently rated higher when reported by interview.


Assuntos
Dispepsia/diagnóstico , Gastroenteropatias/diagnóstico , Inquéritos e Questionários , Testes Respiratórios , Dispepsia/epidemiologia , Dispepsia/fisiopatologia , Feminino , Gastroenteropatias/epidemiologia , Gastroenteropatias/fisiopatologia , Infecções por Helicobacter/diagnóstico , Infecções por Helicobacter/epidemiologia , Humanos , Pessoa de Meia-Idade , Reprodutibilidade dos Testes , Fatores de Risco , Sensibilidade e Especificidade
20.
Br J Dermatol ; 154(5): 880-4, 2006 May.
Artigo em Inglês | MEDLINE | ID: mdl-16634890

RESUMO

BACKGROUND: Eruptive naevi have been described to potentially arise in immune compromised patients. OBJECTIVES: We describe three patients with eruptive benign melanocytic naevi during a phase of immunosuppressive therapy. METHODS/DIAGNOSIS: Two patients with Crohn disease were treated with either azathioprine monotherapy or a combination of azathioprine and infliximab, when eruptive naevi arose particularly at the palms and soles. Our third patient with plaque psoriasis developed eruptive naevi during two episodes of treatment: during a course with the biological agent alefacept and during etanercept therapy. CONCLUSIONS: We conclude that treatment with the recently available biological agents might be associated with the formation of eruptive naevi. Although positive evidence for the occurrence of malignant pigmented lesions is lacking, alertness to the development of eruptive melanocytic naevi during treatment with biological agents is indicated.


Assuntos
Toxidermias/etiologia , Fatores Imunológicos/efeitos adversos , Imunossupressores/efeitos adversos , Nevo Pigmentado/induzido quimicamente , Neoplasias Cutâneas/induzido quimicamente , Adulto , Azatioprina/efeitos adversos , Toxidermias/imunologia , Toxidermias/patologia , Feminino , Humanos , Hospedeiro Imunocomprometido , Masculino , Pessoa de Meia-Idade , Nevo Pigmentado/imunologia , Nevo Pigmentado/patologia , Neoplasias Cutâneas/imunologia , Neoplasias Cutâneas/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA